iSpecimen Inc. Appoints New CMO, Elects Director
Ticker: ISPC · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1558569
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
iSpecimen beefs up leadership with a new CMO and board member.
AI Summary
On December 13, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Mr. David J. Miller to its Board of Directors. The company also reported on compensatory arrangements for certain officers. These changes are effective immediately.
Why It Matters
The appointment of a Chief Medical Officer and a new board member suggests strategic shifts in leadership and potentially a focus on medical expertise within the company's operations.
Risk Assessment
Risk Level: low — This filing primarily concerns personnel changes and does not appear to involve significant financial transactions or operational disruptions.
Key Players & Entities
- iSpecimen Inc. (company) — Registrant
- Dr. Jonathan S. Roth (person) — Appointed Chief Medical Officer
- Mr. David J. Miller (person) — Elected to Board of Directors
- December 13, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for iSpecimen Inc.?
Dr. Jonathan S. Roth has been appointed as the new Chief Medical Officer for iSpecimen Inc.
Who has been elected to the Board of Directors at iSpecimen Inc.?
Mr. David J. Miller has been elected to the Board of Directors at iSpecimen Inc.
What is the effective date of these reported changes?
The earliest event reported is dated December 13, 2024, and the changes are effective immediately.
What specific items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as other events and financial statements/exhibits.
What is the principal executive office address for iSpecimen Inc.?
The principal executive office address for iSpecimen Inc. is 8 Cabot Road, Suite 1800, Woburn, MA 01801.
Filing Stats: 718 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-12-20 17:27:08
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share ISPC The Nasdaq Stock Mar
- $25,000 — ngagement provides for a monthly fee of $25,000 USD, plus applicable taxes and certain
Filing Documents
- ea0225487-8k_ispecimen.htm (8-K) — 26KB
- ea022548702ex10-1_ispecimen.htm (EX-10.1) — 20KB
- ea022548702ex99-1_ispecimen.htm (EX-99.1) — 5KB
- 0001213900-24-111290.txt ( ) — 230KB
- ispc-20241213.xsd (EX-101.SCH) — 3KB
- ispc-20241213_lab.xml (EX-101.LAB) — 33KB
- ispc-20241213_pre.xml (EX-101.PRE) — 22KB
- ea0225487-8k_ispecimen_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 13, 2024, the Board of Directors (the "Board") of iSpecimen Inc. (the "Company") appointed Mr. Yuying Liang, CPA as Chief Financial Officer ("CFO") of the Company, effective immediately. The appointment is made pursuant to the terms of an engagement letter dated December 13, 2024, between the Company and Yuying Liang Professional Corp., a Canadian corporation wholly owned and controlled by Mr. Liang. Under the terms of the engagement, Yuying Liang Professional Corp. will provide ongoing bookkeeping, accounting, financial reporting, and CFO services to the Company. The engagement provides for a monthly fee of $25,000 USD, plus applicable taxes and certain expenses. The engagement may be terminated by either party with 60 days' written notice. The agreement also includes customary terms, such as limitations of liability and provisions for disbursements. The foregoing description of the engagement letter does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. Mr. Liang is a certified public accountant with significant experience in corporate accounting, financial reporting, and CFO services. Mr. Liang has worked extensively with public and private companies across multiple sectors, providing financial leadership and strategic guidance. There are no family relationships between Mr. Liang and any of the Company's directors or executive officers. Additionally, there are no related party transactions requiring disclosure under Item 404(a) of Regulation S-K.
01 Other Events
Item 8.01 Other Events. On December 20, 2024, the Company issued a press release announcing its strategic initiatives for 2025, including its expanded focus on procuring high-demand cancer biospecimens to enhance its support for cancer research. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Engagement Letter between iSpecimen Inc. and Yuying Liang Professional Corp., dated December 13, 2024. 99.1 Press Release dated December 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 20, 2024 iSPECIMEN INC. By: /s/ Robert Bradley Lim Name: Robert Bradley Lim Title: Chief Executive Officer 2